Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA) on Tuesday announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted applications for TVB-009P, a biosimilar candidate to Prolia (denosumab).
Both applications include all indications approved for Prolia, including conditions with a high risk for fracture such as osteoporosis in postmenopausal women. The FDA and EMA are expected to make decisions in the second half of 2025.
TVB-009P is the first internally developed biosimilar from Teva to be submitted to the FDA. The submissions are supported by a comprehensive data package, including results from Phase 3 clinical trials and pharmacokinetic studies.
Osteoporosis affects millions of women worldwide, increasing their risk of bone fractures. Teva's biosimilar candidate, if approved, could offer a new treatment option for patients with this condition.
Gilead showcases efficacy of twice-yearly lenacapavir for HIV prevention at IAS 2025
Merck announces Phase 3 trials for once-monthly oral HIV prevention pill MK-8527
GSK announces submission of RSV vaccine Arexvy for FDA review
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
IGI and AbbVie enter global licensing agreement for ISB 2001
REGENXBIO reports RGX-202 preclinical results in Duchenne Muscular Dystrophy
MetaVia doses first patient in 48 mg MAD cohort of DA-1726 Phase 1 trial
GenScript Biotech awarded EcoVadis Silver Medal
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university